About The Report. Key Questions Answered in this Report:

Transcription

1

2 About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise. IMARC s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3 About The Report IMARC s new report Japan Diabetes Market Report & Forecast provides an analytical and statistical insight into the Japanese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in Japan. The report has segmented the Japanese diabetes market into two segments Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules. The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Japanese diabetes market till This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Japanese diabetes market in some form or the other. Key Questions Answered in this Report: What is the size and demographical breakup of the diabetes population in Japan? What are the current and future diagnosis and drug treatment rates of diabetes in Japan? How has the diabetes market behaved since 2005 and what are the expected trends till 2016? What has been the historical performance of the Japanese Insulin market during and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during ? What has been the historical performance of the Oral Antidiabetics market during and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during ?

4 Why should you buy this report? Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in Japan and identify your potential patient pool. Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans. Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Japanese Insulin and Oral Antidiabetics market. Gain an insight into future market events such as patent expiry s and new product launches. Classes Covered: Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate acting Insulins, Biguanides, Glitazone and Biguanide combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, DPP-IV Inhibitor and Glitazone Combinations, Glinide and Biguanide Combinations, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, SGLT Inhibitors and all other Oral Antidiabetic classes. Information Sources: Information has been sourced from both primary and secondary sources: Primary sources include industry surveys and face to face/telephonic interviews with physicians and industry experts. Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases. Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.

5 Table of Contents 1 Research Methodology & Market Definitions Executive Summary Epidemiology Total Diabetes Patients Patients by Gender Patients by Age Group Diagnosed and Drug Treated Population Market Dynamics Diabetes Market Current Trends ( ) Market Forecast ( ) Insulin Market Current Trends ( ) Market by Class Market by Molecule Top Players Top Drugs Forecast ( ) Oral Antidiabetics Current Trends ( ) Market by Class Top Players Top Drugs Forecast ( )... 34

6 List of Figures Figure 3-1: Japan: Number of Diabetes Patients* (in 000 s), 2010, 2015, 2020, 2025 & Figure 3-2: Japan: Breakup of Diabetes Patients by Gender (in 000 s), 2010, 2015, 2020, 2025 & Figure 3-3: Japan: Breakup of Diabetes Patients by Gender (in %) 2010, 2015, 2020, 2025 & Figure 3-4: Japan: Breakup of Diabetes Patients by Age Group (in 000 s), 2010, 2015, 2020, Figure 3-5: Japan: Breakup of Number of Diabetes Patients by Age Group (in %) Figure 3-6: Japan: Diagnosed & Drug Treated Share of Population Forecast, (in Million) 2010, 2015 & Figure 4-1: Japan: Diabetes Market (in Million US$), Figure 4-2: Japan: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), Figure 4-3: Japan: Diabetes Market Forecast (in Million US$), Figure 4-4: Japan: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), Figure 4-5: Japan: Insulin Market, (in Million US$), Figure 4-6: Japan: Breakup of Insulin Market by Class (in %), Figure 4-7: Japan: Breakup of Insulin Market by Molecule (in %), Figure 4-8: Japan: Insulin Market: Share of Key Players (in %), Figure 4-9: Japan: Insulin Market: Share of Key Drugs (%), Figure 4-10: Japan: Insulin Market Forecast (in Million US$), Figure 4-11: Japan: Oral Antidiabetics Market: (in Million US$), Figure 4-12: Japan: Oral Antidiabetics Market: Share by Class (%), Figure 4-13: Japan: Oral Antidiabetics Market: Share of Key Players (%), Figure 4-14: Japan: Oral Antidiabetics Market: Share of Key Drugs (%), Figure 4-15: Japan: Oral Antidiabetics Market: Forecast (in Million US$), Figure 4-17: Japan: Oral Antidiabetics Market: Share by Class Forecast (%),

7 List of Tables Table 1-1: Japan: Diabetes Market: Market Definitions... 8 Table 2-1: Japan: Diagnosed & Drug Treated Population in Million, 2010, 2015 & Table 3-1: Japan: Breakup of Insulin Market by Class (in Million US$), Table 3-2: Japan: Breakup of Insulin Market by Molecule (in Million US$), Table 3-3: Japan: Insulin Market: Sales of Key Players (in Million US$), Table 3-4: Japan: Insulin Market: Sales of Top Drugs (in Million US$), Table 3-5: Japan: Oral Antidiabetics Market: Sales by Class (in Million US$), Table 3-6: Japan: Oral Antidiabetics Market: Sales of Key Players (in Million US$), Table 3-7: Japan: Oral Antidiabetics Market: Sales of Top Drugs( in Million US$), Table 3-8: Japan: Oral Antidiabetics Market: New Drug Launches ( ) Table 3-9: Japan: Oral Antidiabetics Market: Sales by Class Forecast, (in Million US$), 2010, 2013 &

8 1 Research Methodology & Market Definitions Market definitions used in this report: For the purpose of this report IMARC defines the diabetes market consisting of Oral Antidiabetics and Insulin. Oral Antidiabetics and Insulin can be further divided into the classes as shown in the table below: Table 1-1: Japan: Diabetes Market: Market Definitions Oral Antidiabetics Biguanide Antidiabetics Sulphonylurea Antidiabetics Glitazone Antidiabetics Glinide Antidiabetics Diabetes Market Insulin Fast Acting Long Acting Intermediate and Fast Acting Intermediate Acting Alpha-Glucosidase Inhibitor Antidiabetics DPP-IV Inhibitor Antidiabetics GLP-1 Agonist Antidiabetics Glitazone and Biguanide Antidiabetic Combinations DPP-IV and Glitazone Antidiabetic Combinations Glinide and Biguanide Antidiabetic Combinations SGLT Inhibitor Antidiabetics Other Drugs for Diabetes

9 Diabetes Patients: The total diabetes patients (unless otherwise specified) have been taken as the sum of both type-1 and type-2 diabetes patients. Currency: All sales figures have been shown in US$ (United States Dollars). Rounding offs: Data have been rounded off in tables and charts, as a result of which numbers may/may not add upto totals. Information Sources: Information has been sourced from both primary and secondary sources: Primary sources include industry surveys and face to face/telephonic interviews with physicians and industry experts. Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases. Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast. imarc 9

10 % Population in 000's 3.3 Patients by Age Group In 2010, around 61.5% of the total diabetes patients were above 60 years of age. By 2030, this proportion will decline marginally to 61% whereas the proportion of diabetes patients falling in the age group will increase from 33.3% in 2010 to 35.4% in This suggests that the prevalence of diabetes is increasing in younger patients. Figure 3-4: Japan: Breakup of Diabetes Patients by Age Group (in 000 s), 2010, 2015, 2020, 2025 & ,000 4,000 3,000 2,000 1, Source: International Diabetes Federation & IMARC Group *Note: Age Figure 3-5: Japan: Breakup of Number of Diabetes Patients by Age Group (in %) 2010, 2015, 2020, 2025 & % 80% 60% 40% 20% 0% 61.5% 61.4% 61.3% 61.1% 61.0% 33.3% 33.8% 34.3% 34.9% 35.4% 5.3% 4.8% 4.4% 4.0% 3.6% Source: International Diabetes Federation & IMARC Group *Note: Age imarc 15

11 % Population in Million 3.4 Diagnosed and Drug Treated Population In 2010, out of the total diabetes population, 71% were diagnosed and 52% were drug treated. Diagnosis rates in Japan were lowest in comparison to other developed countries like the UK, France, Germany, Spain and Italy but higher than the US. Drug treatment rates in Japan were lower than most other developed countries. By 2020 we expect diagnosis and drug treatment rates to reach 74% and 58% respectively. Table 3-1: Japan: Diagnosed & Drug Treated Population (in Million), 2010, 2015 & 2020 Population Total Diabetes Population Diagnosed Population Drug Treated Population Source: IMARC Group *Note: Age Figure 3-6: Japan: Diagnosed & Drug Treated Share of Population Forecast, (in %) 2010, 2015 & % % 60% 50% 40% 30% 20% 10% % Total Population Diagnosed Drug Treated Source: IMARC Group *Note: Age imarc 16

12 % in Million US$ Top Players The following trends were observed in the last five years: The Japanese Insulin market is highly concentrated with only three players accounting for the entire market in Novo Nordisk has been the leader in this market for the past five years and accounted for 67% of the total market in Novo Nordisk has five drugs in this class with Novorapid being its leading drug. Driven by the strong performance of Lantus, Sanofi-Aventis has shown the highest growth during As a result of the declining sales of its Humulin brands, Lilly s market share has declined from 21% in 2005 to 18% in Table 4-3: Japan: Insulin Market: Sales of Key Players (in Million US$), Sales By Players Novo Nordisk Lilly Sanofi Aventis Total Source: IMARC Group Figure 4-8: Japan: Insulin Market: Share of Key Players (in %), % 70% 60% 50% % 30% 20% 10% % Total Insulin Market Novo Nordisk Lilly Sanofi Aventis Source: IMARC Group imarc 23

13 Market by Class The following are the highlights of the class trends in this market: Alpha Glucosidase Inhibitors currently represent the biggest oral Antidiabetic class accounting for 35% of the total Oral Antidiabetics market in Unlike the US and European markets, the FDA s black box warning had no effect on the sales of Glitazones. During , the market share of this class increased from 12% in 2005 to 26% in Sulphonylureas have witnessed a marginal decline in their market share during In 2010, they accounted for 16% of the total Oral Antidiabetics market. DPP-IV Inhibitors have witnessed a good uptake in their sales from 2009 accounting for 3% of the entire Oral Antidiabetics market in This trend can be accredited to the strong sales of Sitagliptin. Table 4-5: Japan: Oral Antidiabetics Market: Sales by Class (in Million US$), Market Share by Class Alpha Glucosidase Inhibitors Glitazone Antidiabetics, plain Sulphonylurea Antidiabetics Glinide Antidiabetics, plain Other Drugs for Diabetes Biguanide Antidiabetics, plain DPP-IV inhibitor Antidiabetics, plain Total 1,632 1,656 1,809 1,896 1,988 2,088 Source: IMARC Group imarc 28

14 % in Million US$ Figure 4-12: Japan: Oral Antidiabetics Market: Share by Class (%), % 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% ,500 2,000 1,500 1, Total OADS Market Alpha Glucosidase Inhibitors Glitazone antidiabetics, plain Sulphonylurea Antidiabetics Glinide antidiabetics, plain Other Drugs For Diabetes Biguanide antidiabetics, plain DPP-IV inhibitor antidiabetics, plain Source: IMARC Group imarc 29

15 Other Related Reports Global Diabetes Market Report & Forecast ( ) US Diabetes Market Report & Forecast ( ) Saudi Arabia Diabetes Market Report & Forecast ( ) Germany Diabetes Market Report & Forecast ( ) Italy Diabetes Market Report & Forecast ( ) UK Diabetes Market Report & Forecast ( ) Spain Diabetes Market Report & Forecast ( ) China Diabetes Market Report & Forecast ( ) Russia Diabetes Market Report & Forecast ( ) Brazil Diabetes Market Report & Forecast ( ) Mexico Diabetes Market Report & Forecast ( ) Turkey Diabetes Market Report & Forecast ( ) Middle East Diabetes Market Report & Forecast ( ) Egypt Diabetes Market Report & Forecast ( ) France Diabetes Market Report & Forecast ( ) imarc 37

16 Algeria Diabetes Market Report & Forecast ( ) UAE Diabetes Market Report & Forecast ( ) Kuwait Diabetes Market Report & Forecast ( ) Emerging Diabetes Markets Report & Forecast ( ) imarc 38

17 2010 IMARC All Rights Reserved This Publication and all it s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies. imarc 39